Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

Publication Date: April 19, 2022

Key Points

Key Points

This guideline update provides evidence-based recommendations to optimally use currently available biomarkers in the population of women presenting with early-stage breast cancer with known estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) status.

Diagnosis

...Diagnosis...

...Newly Diagnosed...

...Oncotype DX (21-...

...ecommendation 1.1If a patient has node-negat...

...n 1.2In the group of patients in Recomm...

...tion 1.3In the group of patients in Recomme...

...mendation 1.4If a patient is postmenopausal and...

...ion 1.5In the group of patients in Re...

...ation 1.6If a patient is premenopausal...

...dation 1.7If a patient has node-positive breast ca...

...MammaPrint (70-gen...

...ndation 1.8If a patient is older than 50...

...mmendation 1.9If a patient is 50 years of age or y...

...on 1.10If a patient has low clinical r...

...1.11If a patient has node-positive breast cancer...

...EndoPredict (12-g...

...n 1.12If a patient is postmenopausa...

...ation 1.13If a patient is premenopausal...

...tion 1.14If a patient has breast cancer with...

...Prosigna (PAM50)...

...1.15If a patient is postmenopausal and h...

...1.16If a patient is premenopausal, and ha...

...mmendation 1.17If a patient is postmenopa...

...ation 1.18If a patient has node-positive...

...Mamm...

There is insufficient evidence to r...

...Breast Cancer...

...ent has ER-positive, HER2-negative, node-ne...

...ent has ER-positive, HER2-negative, node-...

...Ki67

...ecommendation 1.19If a patient is postmenopausal...

...mendation 1.20If a patient is postme...

...ion 1.21Despite the limitations associate...

...Immunohistochemis...

...ecommendation 1.22If a patient has node-negative...

...uPA and P...

...a patient has ER-positive, HER2-negative...

...atient has HER2-positive breast canc...


...Extended Endocrine...

...Oncotype DX...

...mmendation 1.23If a patient has node-n...

...BCI...

...ndation 1.24If a patient has node-negative or n...

...ecommendation 1.25If a patient has node-po...

...Clinic...

...1.26If a patient is postmenopausal and had invasi...


...HER2-positive...

...Oncotype D...

...tion 1.27If a patient has HER2-posit...


...Emerging...

...Tumor-Infiltrating Ly...

Recommendation 1.28If a patient has node-negative...

...PD-L1 Te...

...1.29If a patient has node-negative or node-positiv...

...Circul...

...1.30If a patient has node-negative or node-posi...

...Circulating T...

...n 1.31If a patient has node-negative...


...Cancer Biomarkers to Guide Adjuvant Ther...


...1. Algorithm on Biomarkers to Guide Dec...


.... Classification of Patients According...


...ASCO believes that cancer clinical...